Favorable Media Coverage Somewhat Unlikely to Affect GW Pharmaceuticals PLC- (GWPH) Share Price
Media headlines about GW Pharmaceuticals PLC- (NASDAQ:GWPH) have been trending positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GW Pharmaceuticals PLC- earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.0786438232113 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Financial Survey: GW Pharmaceuticals PLC- (GWPH) versus Its Peers (americanbankingnews.com)
- Picton Mahoney Asset Management Has Boosted Electronic Arts (EA) Holding By $3.79 Million; 11 Analysts Bullish GW … – Hill Country Times (hillcountrytimes.com)
- GW Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark (finance.yahoo.com)
- GW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session – Nasdaq (nasdaq.com)
- Analysts Anticipate GW Pharmaceuticals PLC- (GWPH) Will Post Quarterly Sales of $2.14 Million (americanbankingnews.com)
Several equities analysts have weighed in on GWPH shares. ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Leerink Swann reissued an “outperform” rating and set a $153.00 price target (down previously from $160.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Cowen reissued an “outperform” rating and set a $165.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $208.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Finally, Goldman Sachs Group reissued a “neutral” rating and set a $124.00 price target on shares of GW Pharmaceuticals PLC- in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $148.78.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.